PDCD1 and Miyoshi myopathy: Although the definitive conclusions of the anti-PD1/PD-L1 antibody studies have not yet been reported, administering immune checkpoint anti-PD1 or anti-PD-L1 antibodies either alone or in combination with the alternative-type inhibitor such as an CTLA-4 antibody appears to confer some benefits to a subset of patients with MM [23].